Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - USD ($)	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Balance at Dec. 31, 2019		$ 55,739	$ 3,039,163	$ (4,894,881)	$ (11,622)	$ (1,811,601)
Balance, shares at Dec. 31, 2019		5,573,915
Common stock issued for accounts payable		$ 859	172,623			173,482
Common stock issued for accounts payable, shares		85,942
Warrants issued in conjunction with notes payable			32,149			32,149
Beneficial conversion feature issued with note payable			17,851			17,851
Foreign exchange gain/loss					(12,698)	(12,698)
Net loss				(1,098,461)		(1,098,461)
Balance at Mar. 31, 2020		$ 56,598	3,261,786	(5,993,342)	(24,320)	(2,699,278)
Balance, shares at Mar. 31, 2020		5,659,857
Balance at Dec. 31, 2020	$ 32,754	$ 100,951	15,222,770	(11,759,557)	(181,277)	3,415,641
Balance, shares at Dec. 31, 2020	3,275,407	10,095,109
January 2021 registered direct offering		$ 22,213	4,594,874			4,617,087
January 2021 registered direct offering, shares		2,221,334
February 2021 registered direct offering		$ 30,070	6,986,331			7,016,401
February 2021 registered direct offering, shares		3,007,026
Stock based compensation			3,591,565			3,591,565
Induced conversion of stock options into restricted stock awards			298,714			298,714
Conversion of Series B preferred stock	$ (32,754)	$ 32,754
Conversion of Series B preferred stock, shares	(3,275,407)	3,275,407
Exercise of warrants		$ 8,511	3,258,734			3,267,245
Exercise of warrants, shares		851,099
Foreign exchange gain/loss					35,736	35,736
Net loss				(3,250,711)		(3,250,711)
Balance at Mar. 31, 2021		$ 194,499	$ 33,952,988	$ (15,010,268)	$ (145,541)	$ 18,991,678
Balance, shares at Mar. 31, 2021		19,449,975